Clin Exp Vaccine Res.
2014 Jul;3(2):168-175. 10.7774/cevr.2014.3.2.168.
Current status of human papillomavirus vaccines
- Affiliations
-
- 1Eyegene Inc., Seoul, Korea. white@eyegene.co.kr
- KMID: 1730621
- DOI: http://doi.org/10.7774/cevr.2014.3.2.168
Abstract
- Cervical cancer is a malignant neoplasm arising from cells that originate in the cervix uteri. It is the second most prevalent cancer among women. It can have several causes; an infection with some type of human papillomavirus (HPV) is the greatest risk factor for cervical cancer. Over 100 types of HPVs have been identified, and more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region. Among these, a number of HPVs types, containing types 16 and 18, are classified as "high-risk" HPVs that can cause cervical cancer. The HPVs vaccine prevents infection with certain species of HPVs associated with the development of cervical cancer, genital warts, and some less common cancers. Two HPVs vaccines are currently on the global market: quadrivalent HPVs vaccine and bivalent HPV vaccine that use virus-like particles as a vaccine antigen. This review discusses the current status of HPVs vaccines on the global market, clinical trials, and the future of HPVs vaccine development.
